Brief: Chiesi Global Rare Diseases And Protalix Biotherapeutics Announce European Commission Authorization Of PRX-102
05/05/2023 12:31
May 5 (Reuters) - Protalix Biotherapeutics Inc PBDA.F :
* CHIESI GLOBAL RARE DISEASES AND PROTALIX BIOTHERAPEUTICS
ANNOUNCE EUROPEAN COMMISSION AUTHORIZATION OF PRX-102
(PEGUNIGALSIDASE ALFA) FOR THE TREATMENT OF FABRY DISEASE
Source text for Eikon: ID:nPn3Tn906a
Further company coverage: PBDA.F
((Reuters.Brief@thomsonreuters.com;))
Recent news on Protalix BioTherapeutics
See all newsIsrael's Protalix Q2 revenue rises on Elfabrio sales, reiterates 2026 outlook
Israel's Protalix Q1 revenue surges on Chiesi milestone
Brief: Protalix BioTherapeutics Q1 EPS USD 0.23
Brief: Protalix Biotherapeutics Reports Fiscal Year 2025 Financial And Business Results
Brief: EU Approves Four‑week Dosing Option For Chiesi and Protalix’s Elfabrio